ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Glatiramyl 40 mg/ml, Injektionslösung in einer Fertigspritze:Viatris Pharma GmbH
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
L03AX13 - Glatiramer AcetateATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L03 - Immunostimulants

Immunosuppressants, see L04A.

L03A - Immunostimulants

Levamisole, which also affects the immune response, is classified in P02CE.

L03AX - Other Immunostimulants
 

The DDD for tasonermin is based on single dose treatment.
The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).

L03AX13 - Glatiramer Acetate
DoseRoute of administrationNote
 P 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home